About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India, specialising in the research, development, manufacturing and sale of branded generics, generics, specialty medicines and OTC products across therapeutic areas including dermatology, respiratory, oncology, cardiology, diabetes, gynaecology, gastroenterology and anti‑infectives. The company operates in more than 80 countries, supported by 11 state‑of‑the‑art manufacturing sites and 4 R&D centres worldwide . Its shares are listed on the National Stock Exchange of India and BSE Limited.

Founded in 1977 by Mr. Gracias Saldanha, Glenmark’s journey features milestones such as: entry into dermatology with Candid Cream in 1979; the first manufacturing unit in Nashik in 1983; entry into respiratory care with Ascoril in 1987; the first R&D centre at Sinnar in 1999; establishing its North American subsidiary in 2003; European entry in 2004; and commissioning a US manufacturing facility at Monroe, North Carolina in 2014 . Recent strategic milestones include the creation of Ichnos Glenmark Innovation (IGI), out‑licensing agreements, and the completed divestment of a 75% stake in Glenmark Life Sciences to Nirma Limited.

Glenmark has sharpened its focus through “Glenmark 3.0” on its core therapy areas—Oncology, Dermatology and Respiratory—while continuing to build its pipeline via IGI and global in‑licensing partnerships . As of March 31, 2025, the Group comprised 43 subsidiaries, 37 of which were located outside India.

Glenmark Pharmaceuticals Limited Business Segments

• Revenue by geography (FY 2025): India 33.7%; North America 22.6%; Europe 21.4%; Emerging Markets (Asia‑Pacific, Middle East & Africa, Russia & CIS, and Latin America) 21.1%.
• Revenue by market: International markets contributed 66%, with India at 34%.

Glenmark Pharmaceuticals Limited Key Management

• Glenn Saldanha – Chairman & Managing Director
• Cherylann Pinto – Executive Director
• S Mani – Executive Director & Global Chief Financial Officer
• Harish Kuber – Company Secretary & Compliance Officer

Latest Updates on Glenmark Pharmaceuticals Limited

• Oncology launches in India: TEVIMBRA (tislelizumab) for NSCLC and Brukinsa (zanubrutinib) for haematological malignancies.
• Dermatology expansion: Winlevi (clascoterone cream 1%) received MHRA approval in the UK; launches across select European markets are planned for FY 2026.
• Respiratory growth: Ryaltris was launched in more than 11 markets in FY 2025 and is now commercialised in 44 markets globally.
• US generics momentum: 8 ANDA approvals and 13 product launches across oral solids, injectables, a semi‑solid ointment and an oral contraceptive in FY 2025.
• Strategic partnerships: Collaborations included in‑licensing with global partners such as Pfizer (Abrocitinib; India brand name Jabryus), as well as arrangements related to Winlevi in Europe and South Africa.
• Portfolio reshaping: Completed divestment of 75% stake in Glenmark Life Sciences to Nirma Limited.